Results 231 to 240 of about 1,089,170 (344)
P10.31: Nuchal translucency and ductus venosus assessment at 10–16 weeks of multiple pregnancies and chromosomal abnormalities [PDF]
M. Torrents+10 more
openalex +1 more source
This study presents a Ti3C2Tx MXene/WPU nacre‐mimetic nanomaterial as a printable ink for direct‐write printing onto textiles‐based sensors. The resulting wearable device demonstrates high sensitivity, biocompatibility, and mechanical strength. Furthermore, NFC‐enabled humidity sensor produces time‐series data, which informs a machine learning ...
Lulu Xu+6 more
wiley +1 more source
Ultra-wide-field fundus photography and AI-based screening and referral for multiple ocular fundus diseases. [PDF]
Zhao X+36 more
europepmc +1 more source
Evaluating the threshold of abnormal second trimester multiple marker screens (MMS) associated with intra-uterine growth restriction (IUGR) [PDF]
Anthony Odibo+5 more
openalex +1 more source
This paper presents a microphysiological system containing an array of individually addressable living corneal tissues constructed using primary human cells. The bioengineered eye model can simulate acute exposure of the human cornea to different types of environmental toxicants and provides a novel platform for visualization and quantitative ...
Se‐jeong Kim+12 more
wiley +1 more source
Optical Genome Mapping as a New Approach to Detecting Cytogenetic Abnormalities: Why Is It Difficult in Multiple Myeloma? [PDF]
Bayrak Tokaç AG+3 more
europepmc +1 more source
Liquid Crystalline Networks Hamper the Malignancy of Cancer Cells
Liquid Crystalline Networks are used as scaffolds for the growth of A375 melanoma cells demonstrating to affect their malignancy. Indeed, only by contact, these materials reduces cell proliferation and colony formation capacity, while increasing the number of senescent cells and promoting the mesenchymal to epithelial transition.
Daniele Martella+9 more
wiley +1 more source
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies. [PDF]
De Novellis D+3 more
europepmc +1 more source